Evidence map›Paper›PMID 40643493›Full record

ArticleCells2025

Modulation of Neurexins Alternative Splicing by Cannabinoid Receptors 1 (CB1) Signaling.

Elisa Innocenzi, Giuseppe Sciamanna, Alice Zucchi, Vanessa Medici, Eleonora Cesari, Donatella Farini, David J Elliott, Claudio Sette, Paola Grimaldi

Abstract read
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Elisa InnocenziDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
Giuseppe SciamannaDepartmental Faculty of Medicine, UniCamillus-Saint Camillus International University of Health and Medical Sciences, 00131 Rome, Italy.
Alice ZucchiDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0009-0001-6060-6122
Vanessa MediciDepartment of Neuroscience, Section of Human Anatomy, Catholic University of the Sacred Heart, 00168 Rome, Italy.ORCID 0000-0002-0563-8308
Eleonora CesariGSTeP Organoids Research Core Facility, Fondazione Policlinico A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 00168 Rome, Italy.
Donatella FariniDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-1991-3956
David J ElliottNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle NE1 3BZ, UK.ORCID 0000-0002-6930-0699
Claudio SetteDepartment of Neuroscience, Section of Human Anatomy, Catholic University of the Sacred Heart, 00168 Rome, Italy.ORCID 0000-0003-2864-8266
Paola GrimaldiDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0001-6724-7604

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Synaptic plasticity is the key mechanism underlying learning and memory. Neurexins are pre-synaptic molecules that play a pivotal role in synaptic plasticity, interacting with many different post-synaptic molecules in the formation of neural circuits. Neurexins are alternatively spliced at different splice sites, yielding thousands of isoforms with different properties of interaction with post-synaptic molecules for a quick adaptation to internal and external inputs. The endocannabinoid system also plays a central role in synaptic plasticity, regulating key retrograde signaling at both excitatory and inhibitory synapses. This study aims at elucidating the crosstalk between alternative splicing of neurexin and the endocannabinoid system in the hippocampus. By employing an ex vivo hippocampal system, we found that pharmacological activation of cannabinoid receptor 1 (CB1) with the specific agonist ACEA led to reduced neurotransmission, associated with increased expression of the Nrxn1-3 spliced isoforms excluding the exon at splice site 4 (SS4-). In contrast, treatment with the CB1 antagonist AM251 increased glutamatergic activity and promoted the expression of the Nrxn variants including the exon (SS4+) Knockout of the involved splicing factor SLM2 determined the suppression of the exon splicing at SS4 and the expression only of the SS4+ variants of Nrxns1-3 transcripts. Interestingly, in SLM2 ko hippocampus, modulation of neurotransmission by AM251 or ACEA was abolished. These findings suggest a direct crosstalk between CB1-dependent signaling, neurotransmission and expression of specific Nrxns splice variants in the hippocampus. We propose that the fine-tuned regulation of

Indexed as

Alternative SplicingReceptor, Cannabinoid, CB1Signal TransductionAnimalsArachidonic AcidsEndocannabinoidsHippocampusMaleMiceMice, Inbred C57BLNeurexinsNeuronal PlasticityPiperidinesProtein IsoformsPyrazolesSynaptic TransmissionAM 251Arachidonic AcidsEndocannabinoidsNeurexinsPiperidinesProtein IsoformsPyrazolesReceptor, Cannabinoid, CB1alternative splicingcannabinoid receptorsendocannabinoid systemhippocampusneurexin

Identifiers

PMID40643493
PMCPMC12249465

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.